The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).
 
Georgina V. Long
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Provectus; Roche/Genentech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MERCK; Novartis; Provectus; Roche/Genentech
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche/Genentech
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Antoni Ribas
Stock and Other Ownership Interests - Arcus Ventures; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Genentech/Roche; MedImmune; Merck; Novartis; Pierre Fabre
 
Igor Puzanov
Consulting or Advisory Role - Amgen; Roche/Genentech
Travel, Accommodations, Expenses - Amgen
 
Olivier Michielin
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Ari M. Vanderwalde
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Caris Life Sciences; Genentech
 
Robert Hans Ingemar Andtbacka
Honoraria - Amgen; Merck
Consulting or Advisory Role - Amgen; Merck
Research Funding - Amgen (Inst)
 
Jonathan S. Cebon
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis
Consulting or Advisory Role - Amgen (Inst); Bionomics; Bionomics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst)
Research Funding - CSL Behring (Inst); GlaxoSmithKline (Inst)
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline
Expert Testimony - Bristol-Myers Squibb
 
Eugenio Fernandez
Consulting or Advisory Role - Eisai; Novartis
Travel, Accommodations, Expenses - Lilly; Roche
 
Josep Malvehy
Honoraria - Almirall Hermal GmbH; Almirall Hermal GmbH (I); Amgen; Amgen (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); LEO Pharma; LEO Pharma (I); MSD; MSD (I); Novartis; Novartis (I); Roche; Roche (I)
Consulting or Advisory Role - Almirall Hermal GmbH; Almirall Hermal GmbH (I); Amgen; Amgen (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); LEO Pharma; LEO Pharma (I); MSD; MSD (I); Novartis; Novartis (I); Roche; Roche (I)
Speakers' Bureau - Almirall Hermal GmbH; Almirall Hermal GmbH (I); Amgen; Amgen (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); LEO Pharma; LEO Pharma (I); MSD; MSD (I); Novartis; Novartis (I); Roche; Roche (I)
Research Funding - Almirall Hermal GmbH; Almirall Hermal GmbH (I); Almirall Hermal GmbH (Inst); Amgen; Amgen (I); Amgen (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (I); Bristol-Myers Squibb (Inst); ISDIN; ISDIN (I); ISDIN (Inst); LEO Pharma; LEO Pharma (I); LEO Pharma (Inst); Meda; Meda (I); Meda (Inst); MSD; MSD (I); MSD (Inst); Novartis; Novartis (I); Novartis (Inst); Roche; Roche (I); Roche (Inst)
Patents, Royalties, Other Intellectual Property - ISDIN; ISDIN (I); ISDIN (Inst)
Travel, Accommodations, Expenses - Almirall Hermal GmbH; Almirall Hermal GmbH (I); ISDIN; ISDIN (I); Roche; Roche; Roche (I); Roche (I)
 
Anthony J. Olszanski
Consulting or Advisory Role - Janssen; Merck; Takeda
Research Funding - Advaxis (Inst); Amgen (Inst); EMD Serono (Inst); Ignyta (Inst); Immunocore (Inst); Incyte (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); TC Biopharm (Inst)
Travel, Accommodations, Expenses - Takeda
 
Thomas Gajewski
Consulting or Advisory Role - Infinity Pharmaceuticals; Jounce Therapeutics; Merck; Roche/Genentech
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech; GreenPeptide; Roche
Research Funding - Merck (Inst); Prometheus (Inst)
 
Olga Kuznetsova
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Lisa Chen
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Scott J. Diede
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Jeffrey Chou
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
F. Stephen Hodi
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck Sharp & Dohme; Novartis
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche